A REVIEW ON AMORPHOUS SOLID DISPERSIONS AND RECENT ADVANCES
Article Sidebar
Main Article Content
Abstract
Abstract: Amorphous solid dispersion (ASD’s) are most widely used and sought after technique by pharmaceutical industries as there in lot of flexibility in choosing the process, polymers to be used and reproducibility. Currently in this article we discussed about the methods used in formulation of ASD’s in this hot melt extrusion and lyophilization are the techniques mostly preferred in the industrial processes because of their technical advancement and success ratio is more. Drugs which are having solubility issues can be easily formulated in to ASD’s using a suitable solvent system, which is an advantage for many BCS Class II and Class IV drugs where solubility is main factor which effects bio-availability of drugs. Many marketed products are available in the market formulated using ASD’s. Evaluation of ASD’s is done by FT-IR, DSC, XRD and SEM. In this article we emphasized about the polymers used in different techniques of the marketed products which will give a strong proof on reliability of the ASD’s as the successfully applied technique in industries.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Bhujbal, SV., Mitra, B., Jain, U., Gong, Y., Agrawal, A., and Karki, S., 2021. Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies. Acta Pharm Sin B., 11(8):2505–2536.
Vo, CL-N., Park, C., Lee, B-J., 2013. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. Eur J Pharm Biopharm., 85(3): 799–813.
Pandi, P., Bulusu, R., Kommineni, N., Khan, W., and Singh, M., 2020. Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products. Int J Pharm., 586: 119560.
Budiman, A., Handini, AL., Muslimah, MN., Nurani, NV., Laelasari, E., and Kurniawansyah, IS., 2023. Amorphous solid dispersion as drug delivery vehicles in cancer. Polymers., 15(16): 3380.
Schittny, A., Huwyler, J., and Puchkov, M., 2020. Mechanisms of increased bioavailability through amorphous solid dispersions: a review. Drug Delivery., 27(1): 110-127.
Jermain, SV., Brough, C., and Williams, RO., 2018. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery - An update. Int J Pharm., 535(1-2): 379-392.
Van Duong, T., and Van den Mooter, G., 2016. The role of the carrier in the formulation of pharmaceutical solid dispersions. Part II: amorphous carriers. Expert Opin Drug Deliv., 13(2): 1681-1694.
Powell, CT., Cai, T., Hasebe, M., Gunn, EM., Gao, P., and Zhang, G., 2013. Low-concentration polymers inhibit and accelerate crystal growth in organic glasses in correlation with segmental mobility. J Phys Chem B., 117(35): 10334-10341.
Huang, C., Powell, CT., Sun, Y., Cai ,T., and Yu, L., 2017. Effect of low-concentration polymers on crystal growth in molecular glasses: A controlling role for polymer segmental mobility relative to host dynamics. J Phys Chem B., 121(8): 1963-1971.
Van den Mooter, G., Wuyts, M., Blaton, N., Busson, R., Grobet, P., and Augustijns P. 2001. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci., 12(3): 261-270.
Newman, A., and Zografi, G., 2020. What we need to know about solid-state isothermal crystallization of organic molecules from the amorphous state below the glass transition temperature. Mol Pharm., 17(6):1761–1777.
Qi, S., and Craig, D., 2016. Recent developments in micro- and nanofabrication techniques for the preparation of amorphous pharmaceutical dosage forms. Adv Drug Deliv Rev., 100: 67-84.
Singhn, A., and Van den Mooter, G., 2016. Spray drying formulation of amorphous solid dispersions. Adv Drug Deliv Rev., 100: 27-50.
Iyer, R., Petrovska Jovanovska, V., Berginc, K., Jaklic, M., Fabiani, F., and Harlacher, C., 2021. Amorphous solid dispersions (ASDs): The influence of material properties, manufacturing processes and analytical technologies in drug product development. Pharmaceutics, 13(10):1682.
Gala, UH., Miller, DA., and Williams RO., 2020. Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. Biochem Biophys Acta Rev Cancer. 1873(1):188319.
Azad, M., Moreno, J., and Dave, R., 2018. Stable and fast-dissolving amorphous drug composites preparation via impregnation of Neusilin® UFL2. J Pharm Sci., 107(1):170–182.
Yamamoto, K., Kojima, T., Karashima, M., and Ikeda, Y., 2016. Physicochemical evaluation and developability assessment of co-amorphous of low soluble drugs and comparison to the co-crystals. Chem Pharm Bull., 64(12):1739–46.
Arunachalam, A., Karthikeyan, M., Kishore, K., Hari Prasad, P, Sethuraman, S., and Ashutoshkumar, S., 2010. Solid dispersions: a review. Curr Pharm Res., 1(1):82-90.
Andronis, V., Yoshioka, M., and George, Z., 1997. Effects of sorbed water on the crystallization of indomethacin from the amorphous state. J Pharm Sci., 86(3):347.
Gurunath, S., Pradeep Kumar, S., Basavaraj, NK., and Patil, PA., 2013. Amorphous solid dispersion method for improving oral bioavailability of poorly water-soluble drugs. J Pharm Res., 6(4):476–80.
Drooge, ADJ., Hinrichs, WLJ., and Dickhoff, HJ., 2005. Spray freeze drying to produce a stable 9-tetrahydrocannabino containing insulin based solid dispersion powder suitable for inhalation. Eur J Pharm., 26: 231-240.
Yushen, G., Byrn Stephen, R., and Zografi George., 2000. Physical characteristics and chemical degradation of amorphous quinapril hydrochloride. J Pharm Sci., 89(1):128-143.
Puncochova, K., Ewing, AV., and Gajdosova, M., 2015. Identifying the mechanisms of drug release from amorphous solid dispersions using MRI and ATR-FTIR spectroscopic imaging. Int J Pharm., 483:256–67.
Baghel, S., Cathcart, H., and O'Reilly, NJ., 2016. Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci., 105: 2527–44.
Schittny, A., Huwyler, J., and Puchkov, M., 2020. Mechanisms of increased bioavailability through amorphous solid dispersions: a review. Drug Delivery. 27(1):110–27.
Li, S., Liu, Y., Liu, T., Zhao, L., and Feng, N., 2011. Development and in-vivo assessment of the bioavailability of oridonin solid dispersions by the gas anti-solvent technique. Int J Pharm., 411:172-177.
Baghel, S., Cathcart, H., and O'Reilly, NJ., 2016. Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci., 105:2527–44.
Stephenson, Gregory A., Forbes Robert, A., and Reutzel-Edens Susan, M., 2001. Characterization of the solid state: quantitative issues. Elsevier Adv Drug Deliv Rev., 48: 67-90.
Luhadiya, A., Agrawal, S., Jain, P., and Dubey, PK., 2012. A Review on Solid Dispersion. Int J Adv Res Pharm Biosci., 1(2): 281-291.
Gupta, NB., Sharma, P., Bhandari, N., and Singh, K., 2013. To Enhance the Solubility of Poorly Water Soluble Drugs By Using Solid Dispersion: A Review. Int Res J Pharm Appl Sci., 3(2):27-32.
Saberi, A., Kouhjani, M., Yari, D., Jahani, A., Asare-Addo, K., and Kamali H., 2023. Development, recent advances, and updates in binary, ternary co-amorphous systems, and ternary solid dispersions. J Drug Deliv Sci Technol., 86:104746.